3 Life Science Stocks to Sell Now

Advertisement

This week, the ratings of three life science stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Enzo Biochem, Inc. (ENZ) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Enzo Biochem researches, develops, and manufactures health care products based on molecular biology and genetic engineering techniques. ENZ also rates an F in Portfolio Grader’s specific subcategory of Equity. To get an in-depth look at ENZ, get Portfolio Grader’s complete analysis of ENZ stock.

Slipping from a C to a D rating, BG Medicin (BGMD) takes a hit this week. BG Medicine develops and markets diagnostic tests. The stock gets F’s in Equity, Cash Flow and Sales Growth. For more information, get Portfolio Grader’s complete analysis of BGMD stock.

Luminex Corporation (LMNX) earns a D this week, moving down from last week’s grade of C. Luminex develops, manufactures and markets biological testing technologies with applications throughout the clinical diagnostic and life science industries. The stock also rates an F in Earnings Revisions. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. To get an in-depth look at LMNX, get Portfolio Grader’s complete analysis of LMNX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/04/3-life-science-stocks-to-sell-now-enz-bgmd-lmnx-7/.

©2024 InvestorPlace Media, LLC